目的 探讨宫炎康胶囊联合头孢他啶治疗慢性盆腔炎的安全性和有效性。方法 选取2019年1月-2019年8月在商丘市中医院治疗的慢性盆腔炎患者105例，随机分成对照组（52例）和治疗组（53例）。对照组患者静脉滴注注射用头孢他啶，2 g加入250 mL生理盐水，2次/d；治疗组患者在对照组基础上口服宫炎康胶囊，6粒/次，2次/d。两组患者均连续治疗14 d。观察两组患者临床疗效，同时比较治疗前后两组患者VAS评分、临床症状评分、盆腔炎性包块直径，以及血清超敏C反应蛋白（hs-CRP）、糖类抗原125（CA125）、转化生长因子-β1（TGF-β1）水平。结果 治疗后，对照组临床有效率为82.69%，显著低于治疗组的96.23%（P<0.05）。治疗后，两组患者VAS评分、临床症状评分以及盆腔炎性包块直径均显著降低（P<0.05），且治疗组这些指标明显低于对照组（P<0.05）。治疗后，两组患者血清hs-CRP、CA125较治疗前显著下降（P<0.05），而TGF-β1水平显著升高（P<0.05）；且治疗后治疗组患者hs-CRP、CA125、TGF-β1水平明显好于对照组（P<0.05）。治疗组患者的复发率为1.89%，明显低于对照组的13.46%（P<0.05）。结论 宫炎康胶囊联合注射用头孢他啶治疗慢性盆腔炎疗效确切，可显著减轻机体炎症和下腹部疼痛，具有一定的临床推广应用价值。

Objective To explore the safety and efficacy of Gongyankang Capsules combined with ceftazidime in treatment of chronic pelvic inflammatory disease. Methods Patients (105 cases) with chronic pelvic inflammatory disease in Shangqiu City Hospital of TCM from January 2019 to August 2019 were randomly divided into control (52 cases) and treatment (53 cases) groups. Patients in the control group were iv administered with Ceftazidime for injection, 2 g added into 250 mL normal saline, twice daily. Patients in the treatment group were po administered with Gongyankang Capsules on the basis of the control group, 6 grains/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the VAS score, clinical symptom score, pelvic inflammatory mass diameter, the serum levels of hs-CRP, CA125, TGF-β1 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.69%, which was significantly lower than 96.23% in the treatment group (P < 0.05). After treatment, the VAS score, clinical symptom score, pelvic inflammatory mass diameter in two groups were significantly decreased (P < 0.05), and these indexes in the treatment group were significantly lower than that in the control group (P < 0.05). After treatment, the serum levels of hs-CRP and CA125 in two groups were significantly decreased (P < 0.05), but the TGF-β1 levels were significantly increased (P < 0.05), and the levels of hs-CRP, CA125, TGF-β1 in the treatment group were significantly better than those in the control group (P < 0.05). The recurrence rate of 1.89% in the treatment group was significantly lower than 13.46% in the control group (P < 0.05). Conclusion Gongyankang Capsules combined with ceftazidime in treatment of chronic pelvic inflammatory disease is effective, and can significantly reduce the inflammation and abdominal pain, which has a certain clinical application value.

R984